# A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

> **NCT07061574** · PHASE1,PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 120 (estimated)

## Conditions studied

- Type 1 Diabetes
- New Onset

## Interventions

- **DRUG:** Anti-thymocyte globulin (ATG)
- **DRUG:** verapamil extended-release capsule
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT07061574
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2030-04-15
- **Final completion:** 2031-04-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07061574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07061574, "A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07061574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*